Benjamin Haley

This paper introduces Partita, a high-density CRISPRa platform for comprehensive gene activation studies, demonstrating its utility in identifying cancer dependencies and resistance pathways in vitro and in vivo.

This paper develops inducible CRISPR/Cas9 systems with improved dynamic range and reduced off-target effects for precise gene perturbation.

The paper identifies cryptic leukemia antigens that share homology with microbial epitopes and can stimulate T-cell responses in healthy donors, suggesting their potential as targets for T-cell-based immunotherapies.

The paper investigates how immunodominance affects CD8+ T cell differentiation and hierarchy after RNA vaccination, finding that dominant responses influence subdominant ones through cross-competition.

The paper uses a CRISPR/Cas9 screen to identify genes modulating ASO activity, revealing AP1M1 and TBC1D23 as key regulators of endosome-Golgi transport affecting ASO efficacy.

CIPHER uses gene co-fluctuations in unperturbed cells to predict transcriptome-wide responses to perturbations, outperforming existing methods and revealing key regulatory structures.

The paper introduces an enAsCas12a mouse model and associated libraries for efficient gene editing and screening, identifying drug resistance genes and enabling simultaneous gene knockouts and activations.

This paper develops a degron-modified Cas12a system to enable accurate single-cell detection of pre-crRNAs, enhancing Perturb-seq capabilities for multiplex guide expression.

The paper develops a scalable mutagenic base editor platform to identify drug-resistant variants in cancer genomes efficiently.